TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01632475

Intervention type: BIOLOGICAL
Intervention: Pneumostem®
Description: A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg, High Dose Group (6 patients): 2 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study.
Study: NCT04329390

Intervention type: DRUG
Intervention: Anticoagulant drugs
Description: Prescription of, or already on oral anticoagulant treatment.
Study: NCT01872195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The comprehensive patient safety checklist system
Description: The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The comprehensive patient safety checklist system
Description: The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
Study: NCT03923621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EPSiT
Description: Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision
Description: Surgery to remove all affected tissue, followed by wound closure.
Study: NCT03991403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab(Tecentriq)
Description: Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin(AUC 5 or 5.5 IV a); Over approximately 15-30 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel(175 mg/m2 IV); Over 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin or cisplatin
Description: Carboplatin(AUC 5.5 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
Study: NCT04131387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIPUS-1
Description: After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LIPUS-2
Description: The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
Study: NCT04527237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: The person will be given 2 applications a day at 12-hour intervals and 6 applications in 72 hours in total. The session duration of an individual will be approximately 25 minutes.~Physiological measurements will be made before and after the acupressure application. Physiological measurements 10-15 min. From acupressure application. will be taken before and the same measurements after acupressure 20-30. Will be taken again in the min interval. In addition, the Continuous Anxiety Scale will be applied once before application, the State Anxiety Scale will be applied once before the application and 3 times in total after the application at the end of every 24 hours. Sleep Scale will be applied 3 times in total before the next day after application.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Unlike acupressure, it will only be in contact with gloves, to reduce the electrical effect of touch, away from the actual acupressure points.
Study: NCT02934880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immediate APA program
Description: 10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: delayed APA program
Description: 10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
Study: NCT00605098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / ritonavir
Description: Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
Study: NCT00758264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612
Description: Single dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Single dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A
Description: Single dose intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal vaccine GSK1024850A
Description: Single dose intramuscular injection.
Study: NCT04434625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Description: Before colonoscopy, patient-related and procedure-related parameters were collected by one investigator in each center. In MI group, a procedure-based score, used for predicting inadequate bowel preparation, was calculated for each patients. Patients with score ≥3 were asked to taking another dose of PEG (1.5L) within 1-2 hours. Colonoscopy was performed in afternoon (about 4h after drinking PEG). Patients with score\<3 in IM group and those in the control group underwent colonoscopy directly
Study: NCT00201448

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Single dose give IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Towne CMV Vaccine
Description: Single dose given subcutaneously
Study: NCT04392141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Standard Treatment for COVID-19 based on National Recommendations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions
Description: Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
Study: NCT02754141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986179
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986179
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986179
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days
Study: NCT04114643

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prothrombin Complex Concentrate
Description: Octaplex will be administered when the blood bank receives an order for coagulation factor replacement

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Frozen Plasma
Description: Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
Study: NCT01562522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological counseling
Description: Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
Study: NCT03894631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: KDB/Phacoemulsification
Description: 50 eyes of 50 patients will receive combined KDB/phaco surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabectome/Phacoemulsification
Description: The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
Study: NCT05280002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose Tissue derived Total-Stromal-Cells (TOST)
Description: Single dose autologous aAdipose Tissue derived Total-Stromal-Cells (TOST) containing mesenchymal stem cell was injected in each knee of the participants having knee osteoarthritis.
Study: NCT01498575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen driving plan
Description: Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
Study: NCT02007057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene nerve block
Study: NCT03652857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Combined With Vinorelbine
Description: Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
Study: NCT00368836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathScreen PE
Description: One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
Study: NCT01296633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medtable
Description: Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medtable
Description: Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
Study: NCT01467037

Intervention type: OTHER
Intervention: No intervention done
Description: Not applicable because no intervention was done.

Intervention type: OTHER
Intervention: No intervention done
Description: Not applicable because no intervention was done.
Study: NCT00820794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 225 mg q12h PD 0332334, oral, 9 days treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: 300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332334
Description: 225 mg q12h PD 0332334, oral, 9 days treatment
Study: NCT01345591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Study: NCT05332587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The therapeutical schema is rituximab 100-200 mg/week for a total of 2-4 times
Study: NCT01571128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Male-Specific Intervention Package
Description: Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female-Specific Intervention Package
Description: Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Exposure Prophylaxis (Females)
Description: Females 18-24 who are out of school.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Transfer Cohort (Females)
Description: Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
Study: NCT04243018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy Group Treatment
Description: The intervention presents, a mixture of instruction, discussion, and the use of metaphor and experiential activities designed to sensitise participants to the effects of self-stigma and shame on how they live their lives. This training condition provides instruction and experiences that train participants to notice, and then to override, the very human tendency to categorise and then avoid aversive thoughts and feelings and the people and situations that evoke them. The acceptance and commitment training condition will cover the following topics: (a) introduction to enacted and self-stigma (b) cognitive defusion/behavioural flexibility (c) acceptance vs. avoidance and control of emotions and thoughts and (d) values and committed action.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support Group
Description: The peer support group will allow participants to share and discuss experiences related to their experiences of homelessness, shame and stigma. The group will be facilitated by an expert in facilitating peer support groups with marginalised populations.
Study: NCT02121392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine
Description: In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
Study: NCT03649698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo omega-3
Description: Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo omega-3
Description: Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
Study: NCT00873756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dulanermin
Description: Intravenous repeating dose
Study: NCT01635972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride
Description: oral
Study: NCT02228785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study: NCT03227029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV ΔNS2/Δ1313/I1314L
Description: 10\^6 plaque-forming units (PFU); administered as nose drops

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV 276
Description: 10\^5 PFU; administered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic diluent, administered as nose drops
Study: NCT00292695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT
Description: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12
Study: NCT05263323

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Providing patient education to hemodialysis patients according to Neuman Systems Model by the researcher.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Collecting, No Education
Description: Data were collected at the beginning and end of the study without training the control group.
Study: NCT03182101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
Study: NCT03779204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship
Description: The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rent Subsidies
Description: Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rent Subsidies
Description: Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
Study: NCT01124422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol inhalation powder DISKUS 250/50
Description: Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide inhalation powder HandiHaler
Description: Open-label drug also known as Spiriva HandiHaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tiotropium bromide inhalation powder HandiHaler
Description: Open-label drug also known as Spiriva HandiHaler
Study: NCT03383679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: treatment with darolutamide

Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: treatment with capecitabine
Study: NCT01676389

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham OMM
Description: Sham Osteopathic Manual Medicine (OMM).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Medicine (Body Therapy)
Description: OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
Study: NCT01761110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based buprenorphine treatment (CBBT) intervention
Description: Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.